Stocks and Investing
Stocks and Investing
Fri, January 5, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Hartaj Singh Initiated (TRDA) at Buy and Held Target at $22 on, Jan 5th, 2024
Hartaj Singh of Oppenheimer, Initiated "Entrada Therapeutics, Inc." (TRDA) at Buy and Held Target at $22 on, Jan 5th, 2024.
Hartaj has made no other calls on TRDA in the last 4 months.
There is 1 other peer that has a rating on TRDA. Out of the 1 peers that are also analyzing TRDA, 0 agree with Hartaj's Rating of Hold.
This is the rating of the analyst that currently disagrees with Hartaj
- Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $20 on, Monday, November 27th, 2023
Contributing Sources